To evaluate the effects of sustained GCS inhibition in this more robust synucleinopathy model, we performed a long-term treatment study using the pelleted chow formulation of venglustat in Gaucher-related synucleinopathy mice starting at 4 weeks of age (Fig. 3A). Here, UGCG is linked to synucleinopathy.